Psychopharmacology 2019 – What is New, What is Coming?

Objectives

1. Better understanding of newly approved psychotropic medications;
2. Better understanding of new indications for previously approved psychotropic medications; and
3. Better understanding of existing pharmacological treatment-challenges.

Literature References

1. https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
2. http://www.accessdata.fda.gov/scripts/cder/daf/
3. http://www.pre.ethics.gc.ca/pdf/eng/tcps2-2014/TCPS_2_FINAL_Web.pdf

Abstract

While multiple unmet therapeutic needs remain in psychiatry, many pharmaceutical companies have either discontinued or significantly
reduced their drug-development programs for CNS-Disorders. Despite this worrisome trend, several new pharmacological agents, as
well as modifications / new formulations of previously approved medications, have been approved by Health Canada over the past
years. Other medications have received new indications by Health Canada or are under review by Health Canada. For other
medications, new warnings have been issued for potential side-effects.

The following medications will be reviewed in this presentation:
Aripiprazole, Brexpiprazole, Flibanserin, Lurasidone, Methylphenidate, Suvorexant, Vilazodone

I will also review novel antidepressant treatment options that are currently under review by FDA (esketamine) or in the final stages of
clinical trials (rapastinel).